Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Accumulated Expenses (2016 - 2025)

Veracyte's Accumulated Expenses history spans 13 years, with the latest figure at $43.8 million for Q4 2024.

  • For Q4 2024, Accumulated Expenses changed N/A year-over-year to $43.8 million; the TTM value through Dec 2024 reached $43.8 million, changed N/A, while the annual FY2024 figure was $43.8 million, N/A changed from the prior year.
  • Accumulated Expenses for Q4 2024 was $43.8 million at Veracyte, roughly flat from $43.9 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $43.9 million in Q3 2024 and bottomed at $6.7 million in Q2 2020.
  • The 5-year median for Accumulated Expenses is $30.6 million (2023), against an average of $27.7 million.
  • The largest annual shift saw Accumulated Expenses crashed 31.74% in 2020 before it soared 237.25% in 2021.
  • A 5-year view of Accumulated Expenses shows it stood at $11.7 million in 2020, then skyrocketed by 237.25% to $39.5 million in 2021, then decreased by 4.31% to $37.8 million in 2022, then decreased by 18.88% to $30.6 million in 2023, then soared by 43.03% to $43.8 million in 2024.
  • Per Business Quant, the three most recent readings for VCYT's Accumulated Expenses are $43.8 million (Q4 2024), $43.9 million (Q3 2024), and $43.5 million (Q2 2024).